Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | SVP, FINANCE AND CAO | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,828 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 573 · Balance 87,828 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:50 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 573 | $1.93 | $1,105.89 |
DisclosureSEC source: 0001193125-26-355761 · ownership.xml · nonDerivative · entry 1 Wong Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,828 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,404 | $2.04 | $2,864.16 |
DisclosureSEC source: 0001193125-26-296246 · ownership.xml · nonDerivative · entry 1 Wong Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,401 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 903 | $2.17 | $1,959.51 |
DisclosureSEC source: 0001193125-26-119703 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,805 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 565 | $2.27 | $1,282.55 |
DisclosureSEC source: 0001193125-26-061313 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,708 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 192,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001193125-26-027288 · ownership.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2036-01-25 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 3,925 | $1.11 | $4,356.75 |
DisclosureSEC source: 0001193125-26-006374 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,273 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001193125-25-241382 · ownership.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-10-14 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:12 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 611 | $0.64 | $391.28 |
DisclosureSEC source: 0000950170-25-110102 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,198 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025. Read SEC document |
| July 07, 2025 Filed Jul 8, 2025 20:37 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,011 | $0.45 | $905.15 |
DisclosureSEC source: 0000950170-25-094613 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,809 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:22 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,532 | $0.43 | $658.76 |
DisclosureSEC source: 0000950170-25-092232 · ownership.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,820 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001415889-25-010697 · form4-04152025_080416.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-04-11 F1 · derivative.exercise_date: All of the shares subject to the option vest on April 11, 2026. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:45 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008428 · form4-03182025_080356.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,352 F1 · shares: The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:25 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 550 | $1.15 | $632.61 |
DisclosureSEC source: 0001415889-25-005071 · form4-02212025_090224.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,352 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 112,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001965 · form4-01232025_110113.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:10 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,221 | $1.80 | $3,997.80 |
DisclosureSEC source: 0001415889-25-001120 · form4-01082025_090144.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,902 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:46 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,426 | $1.58 | $2,253.37 |
DisclosureSEC source: 0001415889-25-000132 · form4-01022025_090133.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,123 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:15 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001415889-24-028245 · form4-12042024_091224.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-12-01 F1 · derivative.exercise_date: Shares subject to the option vest in 30 equal monthly installments beginning on January 2, 2025. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 21:10 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 564 | $2.58 | $1,455.12 |
DisclosureSEC source: 0001415889-24-021482 · form4-08162024_090836.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,549 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,823 | $5.50 | $10,025.22 |
DisclosureSEC source: 0001415889-24-019429 · form4-07092024_080737.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,113 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $5.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,373 | $5.82 | $7,989.21 |
DisclosureSEC source: 0001415889-24-019228 · form4-07032024_090722.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,936 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $5.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,718 shares acquired under the Issuer's employee stock purchase plan on June 28, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:24 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $15.84 | $0.00 |
DisclosureSEC source: 0001415889-24-004233 · form4-02162024_110202.xml · derivative · entry 2 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:24 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004233 · form4-02162024_110202.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, FINANCE AND CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,591 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on August 14, 2024. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 21:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,717 | $13.60 | $36,956.63 |
DisclosureSEC source: 0001209191-24-000985 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,591 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.59 to $13.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:28 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,631 | $15.04 | $24,530.24 |
DisclosureSEC source: 0001209191-24-000379 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,308 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 1,226 shares acquired under the Issuer's employee stock purchase plan on December 29, 2023. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:19 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001209191-23-043523 · doc4.xml · derivative · entry 2 Pinto Shelly · CIK 0001857740 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-07-24 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 3, 2023. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:19 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043523 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,713 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on December 28, 2023. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 7,345 | $6.52 | $47,889.40 |
DisclosureSEC source: 0001209191-23-041790 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,713 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 466 | $7.34 | $3,420.44 |
DisclosureSEC source: 0001209191-23-041189 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,058 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 1,427 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023. Read SEC document |
| December 29, 2022 Filed Jan 4, 2023 01:52 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 482 | $11.07 | $5,335.69 |
DisclosureSEC source: 0001209191-23-000485 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,097 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.04 to $11.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects a reduction of 139 shares previously reported as acquired pursuant to the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001209191-22-045064 · doc4.xml · derivative · entry 2 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-08-04 F3 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 1, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045064 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,718 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on December 28, 2022. F2 · balance_after: Includes 1,272 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:36 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005923 · doc4.xml · nonDerivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,446 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest as follows: three-eighths of the RSUs vest on July 3, 2023 and the remaining RSUs vest thereafter in five equal semiannual installments. F2 · balance_after: Includes 446 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:28 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $58.56 | $0.00 |
DisclosureSEC source: 0001209191-21-049415 · doc4.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-07-29 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 30, 2021. Read SEC document |
| May 03, 2021 Filed May 19, 2021 21:26 UTC Amendment | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $62.83 | $0.00 |
DisclosureSEC source: 0001209191-21-034072 · doc4a.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on May 3, 2022 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| May 03, 2020 Filed May 5, 2021 20:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $62.83 | $0.00 |
DisclosureSEC source: 0001209191-21-030336 · doc4.xml · derivative · entry 1 Pinto Shelly · CIK 0001857740 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-05-03 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on May 3, 2022 and 1/48th of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.